We are live on
!
Find out more
LBC
Lawrence B. Cohen Portfolio holdings
AUM
$2.06M
1-Year Est. Return
34.47%
This Fund
S&P 500
This Quarter
Est. Return
+4.71%
1 Year Est. Return
+34.47%
3 Year Est. Return
+41.85%
5 Year Est. Return
+126.65%
10 Year Est. Return
+272.7%
AUM
$154M
AUM Growth
-$2.91M
(-1.9%)
Cap. Flow
-$9.15M
Cap. Flow
% of AUM
-5.96%
Top 10 Holdings %
Top 10 Hldgs %
36.45%
Holding
75
New
2
Increased
12
Reduced
48
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Intercontinental Exchange
ICE
|
+$623K |
| 2 |
General Dynamics
GD
|
+$287K |
| 3 |
Novartis
NVS
|
+$180K |
| 4 |
RTX Corp
RTX
|
+$102K |
| 5 |
Newell Brands
NWL
|
+$67.5K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.04M |
| 2 |
Johnson & Johnson
JNJ
|
+$792K |
| 3 |
Edwards Lifesciences
EW
|
+$602K |
| 4 |
Stryker
SYK
|
+$589K |
| 5 |
AMRI
Albany Molecular Research Inc
AMRI
|
+$540K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.96% |
| 2 | Technology | 19.81% |
| 3 | Financials | 10.9% |
| 4 | Industrials | 9.34% |
| 5 | Consumer Staples | 8.32% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Intel
INTC
$460B
| $7.08M | 4.61% |
185,792
-13,700
| -7% | -$487K |
|
2
Microsoft
MSFT
$3.35T
| $6.4M | 4.17% |
85,931
-7,382
| -8% | -$539K |
|
3
Apple
AAPL
$4.9T
| $6.11M | 3.98% |
158,472
-12,084
| -7% | -$469K |
|
|
4
Stryker
SYK
$133B
| $5.55M | 3.62% |
39,102
-4,110
| -10% | -$589K |
|
5
TJX Companies
TJX
$176B
| $5.51M | 3.59% |
149,558
-4,814
| -3% | -$171K |
|
|
6
Edwards Lifesciences
EW
$50B
| $5.22M | 3.4% |
143,235
-15,780
| -10% | -$602K |
|
|
7
State Street SPDR S&P 500 ETF Trust
SPY
$784B
| $5.1M | 3.32% |
20,292
-4,215
| -17% | -$1.04M |
|
8
PepsiCo
PEP
$191B
| $5.03M | 3.28% |
45,136
-2,401
| -5% | -$277K |
|
9
US Bancorp
USB
$98B
| $4.99M | 3.25% |
93,050
-4,513
| -5% | -$236K |
|
10
CVS Health
CVS
$134B
| $4.98M | 3.25% |
61,292
-471
| -0.8% | -$37.3K |
|
11
Cognizant
CTSH
$24.3B
| $4.91M | 3.2% |
67,691
-5,891
| -8% | -$414K |
|
|
RDS.B
12
DELISTED
Royal Dutch Shell PLC ADS Class B
RDS.B
| $4.79M | 3.12% |
76,570
-1,909
| -2% | -$110K |
|
13
iShares MSCI EAFE ETF
EFA
$78.5B
| $4.74M | 3.09% |
69,263
-50
| -0.1% | -$3.34K |
|
14
Rockwell Automation
ROK
$52.4B
| $4.58M | 2.98% |
25,718
-292
| -1% | -$48.6K |
|
15
Procter & Gamble
PG
$335B
| $4.11M | 2.68% |
45,189
-1,185
| -3% | -$108K |
|
16
3M
MMM
$90.8B
| $3.96M | 2.58% |
22,580
-2,602
| -10% | -$451K |
|
17
ExxonMobil
XOM
$651B
| $3.93M | 2.56% |
47,899
-623
| -1% | -$49.5K |
|
18
JPMorgan Chase
JPM
$933B
| $3.74M | 2.44% |
39,156
-764
| -2% | -$70.5K |
|
19
Verizon
VZ
$193B
| $3.69M | 2.4% |
74,489
-3,118
| -4% | -$147K |
|
20
Applied Materials
AMAT
$398B
| $3.36M | 2.19% |
64,469
-5,225
| -7% | -$236K |
|
21
Comcast
CMCSA
$84B
| $3.35M | 2.18% |
86,968
-5,562
| -6% | -$219K |
|
22
Booking.com
BKNG
$150B
| $3.26M | 2.12% |
44,475
-25
| -0.1% | -$1.9K |
|
23
Medtronic
MDT
$110B
| $3.21M | 2.09% |
41,322
-730
| -2% | -$60.6K |
|
24
T. Rowe Price
TROW
$25.6B
| $3.08M | 2% |
33,920
+95
| +0.3% | +$7.86K |
|
25
Biogen
BIIB
$30.7B
| $3.03M | 1.97% |
9,680
+85
| +0.9% | +$25.2K |
|
Similar funds
ICM
TA
SCM
LCMP
GIP
STC
GC
DU
Lawrence B. Cohen's Q3 2017 Portfolio in Review
As of Q3 2017, Lawrence B. Cohen held 75 positions worth $154M, down 1.9% from $156M the previous quarter. Its ten largest holdings account for 36% of the portfolio.
Lawrence B. Cohen withdrew a net $9.15M in Q3 2017, closing 4 positions and reducing 48 holdings. Its most notable exit was Albany Molecular Research Inc, an estimated $540K position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 22% of assets, down from 24% a quarter earlier, followed by Technology and Financials.
Against the trend, Lawrence B. Cohen opened a new position in Intercontinental Exchange worth $649K.
- Lawrence B. Cohen's largest Q3 2017 buy was Intercontinental Exchange: 9,450 shares worth $649K.
- Lawrence B. Cohen added most to Novartis in Q3 2017, an estimated $180K increase.
- Lawrence B. Cohen's biggest Q3 2017 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $1.04M.
- Lawrence B. Cohen fully exited Albany Molecular Research Inc in Q3 2017, selling an estimated $540K.
- Lawrence B. Cohen's ten largest holdings make up 36% of its $154M portfolio in Q3 2017.
- Lawrence B. Cohen opened 2 new positions and closed 4 in Q3 2017.
- Lawrence B. Cohen's portfolio value fell 1.9% quarter-over-quarter to $154M.
Based on Lawrence B. Cohen's 13F filing for Q3 2017, filed 3 Nov 2017.